GOVX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	31 877.00
Average Volume	43 001.00
Market Cap	3.55M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-3.15 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.0320 (2.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Dodd David A	Buy	8 209	Common Stock
2024-02-21	Dodd David A	Buy	520	Common Stock
2024-02-07	Reynolds Mark	Buy	2 000	Common Stock
2023-12-22	Mckee Kelly T. Jr.	Buy	6 944	Common Stock
2023-09-25	Mckee Kelly T. Jr.	Buy	9 653	Common Stock

INSIDER POWER
99.71
Last 95 transactions
Buy: 15 241 679 \| Sell: 50 000

GeoVax Labs, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GeoVax Labs, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-74 169.00 (0.00 %)
EPS:	$-14.29

Q4	2023
Revenue:	$103 912
Gross Profit:	$81 699.00 (78.62 %)
EPS:	$-3.87

Q3	2023
Revenue:	$0
Gross Profit:	$-17 319.00 (0.00 %)
EPS:	$-4.75

Q2	2023
Revenue:	$0
Gross Profit:	$-17 318.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.